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Available online 3 September 2016AbstractPurpose: The aim of the present study was to investigate the effect of subthreshold diode laser micropulse (SDM) in comparison with con-
ventional laser photocoagulation in the treatment of the diabetic macular edema (DME).
Methods: Sixty-eight eyes from 68 patients with clinically significant DME were divided randomly into two equal groups. In the first group,
SDM photocoagulation was employed, while conventional laser photocoagulation was performed on the eyes of the second group. Central
macular thickness (CMT), central macular volume (CMV), and best corrected visual acuity (BCVA) were measured before, 2, and 4 months after
intervention, and the results were compared.
Results: The mean CMT was 357.3 and 354.8 microns before the treatment in Groups 1 and 2, respectively (P ¼ 0.85), and decreased
significantly to 344.3 and 349.8 after 4 months, respectively (P ¼ 0.012 and P ¼ 0.049). The changes in the central macular thickness was
statistically higher in the first group (P ¼ 0.001). The mean CMV significantly decreased in Group 1 (P ¼ 0.003), but it was similar to pre-
treatment in Group 2 after 4 months (P ¼ 0.31). The BCVA improved significantly in Group 1 (P < 0.001), but it remained unchanged in Group 2
(P ¼ 0.38).
Conclusions: In this study, SDM was more effective than conventional laser photocoagulation in reducing CMT and CMVand improving visual
acuity in patients with DME.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1e3Introduction
Diabetic macular edema (DME) is one of the most impor-
tant causes of visual deterioration in working-age patients whoThis study was approved as residency thesis of Isfahan University of
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).have diabetes mellitus. DME was defined as retinal thick-
enings and/or edema threatening or involving the fovea that is
visible by fundus examination or optical coherence tomogra-
phy (OCT). When it involves the fovea, returning to the pre-
vious visual status is almost impossible.4,5 DME is classified as
focal and diffuse. The traditional treatment for macular edema
had been laser photocoagulation, focal laser to induce photo-
coagulation of microaneurysms in focal DME, and grid pattern
laser for diffuse type.6
Currently, intra-vitreal anti vascular endothelial growth
factors (VEGF) injections with or without laser photocoagu-
lation is the standard of care for patients with DME, and newerosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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photocoagulation (SDM) are under investigation in an attempt
to improve the efficacy while reducing the adverse events. The
studies evaluating the safety and efficacy of SDM, in com-
parison with conventional laser therapy for macular edema,
are limited.3,7e9
Our study was designed to compare the efficacy of SDM
with conventional laser as a primary treatment of DME.
Methods
This single-blind, prospective, randomized, clinical trial
was performed in the ophthalmology center of Feiz Hospital,
Isfahan, Iran, between 2015 and 2016. The study was
approved by the Ethics Committee of the Isfahan University
of Medical Sciences and was registered in the Iranian Clinical
Trial Registry (registration number IRCT2015122721890N2).
We explained the aim of our study to the patients, and
informed consent was obtained. Diabetic patients who were
suffering from clinically significant macular edema
(CSME)10 and non-proliferative diabetic retinopathy (NPDR)
in fundus exam were enrolled in the study. The inclusion
criteria of our study were: the minimum best corrected visual
acuity (BCVA) 20/200 or 1.00 Logarithm of the Minimal
Angle of Resolution (LogMAR), the best corrected vision
less than 20/25 or 0.10 LogMAR, and DME with the mini-
mum central macular thickness (CMT) of 300 microns on
OCT basis. The exclusion criteria were: monocular patients,
DME with CMT more than 450 microns on the OCT, preg-
nant patients or pregnancy during the study, uncontrolled
hypertension defined by systolic blood pressure (SBP) more
than 160 mmHg and/or diastolic blood pressure (DBP) more
than 110 mmHg, any history of intra-ocular surgery except
uncomplicated phacoemulsification cataract surgery in past
six months, any history of previous intra-ocular injections,
any history of previous conventional laser photocoagulation
of retina or subthreshold diode micropulse laser, previous
history of glaucoma or ocular hypertension or an increase in
intraocular pressure (IOP) during the study, macular diseases
such as vitreo macular traction (VMT), epi retinal membrane
(ERM), age-related macular degeneration (AMD), extensive
non-capillary perfusion of macula in fluorescein angiography
(FA), any visible scar in ophthalmic examination or fundus
photograph after the study in the group treated with
subthreshold diode micropulse laser, severe cataract not
allowing the surgeon to observe the fundus, and lack of
patient follow-up.
Sixty-eight patients were divided into two equal groups by
block randomization. The first group was treated with SDM
(Quantel-medical Co, Cournon-d'Auvergne, France), and the
second group underwent the conventional macular laser
photocoagulation (Quantel-medical Co, Cournon-d'Auvergne,
France). In both groups, the wavelength of laser therapy was
810 nm.
All laser treatments were performed by an ophthalmologist
(F.F). Prior to starting treatment with SDM, a test burn wasperformed in the nasal side to determine threshold power
required for a visible tissue reaction for each patient. This test
was done with 125 um spot, 200 ms exposure duration, and
adjusted upward the power in the continuous wave (CW)
emission mode until a light grayish visible burn was observed.
When the threshold power of the patient achieved, the laser
was changed to Micro-Pulse emission mode with 15% duty
cycle, and the power was doubled with the same exposure
duration.
SDM was conducted via dilated pupil as follows: adjustable
power began from 1000 milli-joules with duration time of
300 ms, 15% duty cycle, and 75 to 125 micron spot size. All
areas of clinically visible thickened and edematous retina in
the macular area were treated excluding the foveal avascular
zone (FAZ) with a safety margin of 100 microns around FAZ.
Conventional laser photocoagulation was done via dilated
pupil in the eyes of the second group as follows: adjustable
power with 50e100 micron spot size, and 0.1 s duration time.
Focal laser was applied in the distance of 500e3000 microns
of the FAZ as well as on microvascular lesions with an
exudative ring. In addition, grid laser was applied on clinically
visible thickened retina in the macular areas excluding FAZ
and a safety margin of 500-micron around the FAZ and 500-
micron from the optic disc. For both groups, the laser treat-
ment was performed once.
An ophthalmologist carried out laser treatment and the
ophthalmic examination of the patients, including best cor-
rected visual acuity (BCVA), slit lamp biomicroscopy, IOP
measurement using Goldman applanation tonometer, and
fundus examination after pupil dilation to confirm CSME and
NPDR. These examinations and OCTwere repeated in 2 and 4
months after the intervention, and the information of these
evaluations was gathered in special sheets. Only one
ophthalmologist performed all of the examinations and in-
terventions for all of the patients. LogMAR was utilized to
calculate BCVA. Cycloplegic refraction was done by auto-
refractometer (Topcon Medical system Inc. Tokyo, Japan)
before the intervention and 2 and 4 months after the
intervention.
The lens opacity was classified according to lens opacity
classification III11 as nuclear sclerosis, cortical cataract, or
posterior subcapsular. After that, lenses were classified ac-
cording to red reflex and physical examinations such as
observing fundus, vascular branches, and head of optic nerve
and especially surgeon experiments as mild, moderate, and
severe. Very severe dense cataracts were excluded as
explained above.
CMT (microns) was automatically calculated by OCT for
all eyes (SD-OCT Heidelberg Engineering, Heidelberg, Ger-
many). Baseline FA (Heidelberg Engineering Co, Heidelberg,
Germany) was performed to evaluate areas of leakage and
capillary non-perfusion. Fundus photographs (Engineering
Heidelberg Co, Heidelberg, Germany) were taken before and
at the end of the study to compare retinal changes.
After laser therapy, all patients were evaluated for the
following possible complications: vitreous and intra-retinal
Table 2
The mean of best corrected visual acuity, central macular thickness, and
central macular volume before and after the treatment in both groups.
Variables Time Treated groups P Value
SDM CLP
BCVA Before intervention 0.59 ± 0.3 0.58 ± 0.32 0.91a
After 2 months 0.58 ± 0.3 0.59 ± 0.32 0.9a
After 4 months 0.52 ± 0.29 0.6 ± 0.33 0.29a
P value ˂0.001b 0.38b 0.015c
CMT Before intervention 357.3 ± 56.4 354.8 ± 53.3 0.85a
After 2 months 349.2 ± 57.4 353.3 ± 55.3 0.77a
After 4 months 344.3 ± 59.5 349.8 ± 53.7 0.69a
P value 0.012b 0.049b 0.001c
CMV Before intervention 8.62 ± 1.24 8.89 ± 1.23 0.37a
After 2 months 8.49 ± 1.19 8.87 ± 1.25 0.2a
After 4 months 8.42 ± 1.23 8.84 ± 1.25 0.17a
P value 0.003b 0.31b 0.001c
BCVA: best corrected visual acuity; CMT: central macular thickness; CMV:
central macular volume; SDM: subthreshold diode laser micropulse; CLP:
conventional laser photocoagulation.
a The difference between two groups analyzed by t-test.
b The difference within each group analyzed by ANOVA with repeated
measurement test.
c The difference between two groups analyzed by ANCOVA with repeated
measurement test.
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retinal fibrosis, and retinal scar formation. The above-
mentioned complications were assessed by fundus examina-
tion, OCT, and autofluorescence imaging.
Changes in CMT and CMVon the basis of OCT and BCVA
(LogMAR), before and after intervention, were the primary
outcomes. Statistical analysis was performed, using SPSS
software (SPSS Inc, Chicago, IL, USA) version 23. The results
with a level of P < 0.05 were considered statistically signifi-
cant. Paired t test was used to compare the mean of mea-
surements before and after treatment. Furthermore, student t-
test was employed to analyze the quantitative data between the
two groups. The chi-square test was used to compare the
nominal qualitative data. Finally, the changes of quantitative
variables between the two groups were analyzed by ANOVA
with repeated measurement.
Results
34 patients with a mean age of 52.2 ± 6.7 years in the SDM
group and 34 patients with a mean age of 53.7 ± 7.1 years in
the conventional laser group were enrolled in the study. None
of the eyes were excluded from the study during follow-up.
Also, none of the patients needed cataract surgery during the
study. Demographic and baseline characteristics of the patients
are illustrated in Table 1. There was no significant difference
concerning sex, age, the leakage pattern, the duration of the
diabetes, the mean of IOP, the mean of cycloplegic refraction,
and lens opacity between the two groups.
The mean and the standard deviation of BCVA, CMT, and
CMV are summarized in Table 2. There was no significant
difference between BCVA, CMT, and CMV before the treat-
ment and 2 and 4 months after intervention between both
groups (P ˃ 0.05). In Group 1, treated with SDM, BCVA
improved significantly after 4 months (P < 0.001), while this
did not occur in Group 2 (P ¼ 0.38). The mean changes of
BCVA in Group 1 was 0.07 ± 0.01, and þ0.02 ± 0.01 after 4
months in Group 2 (P < 0.001 and P ¼ 0.38, respectively)
(Table 2, Fig. 1).Table 1
Demographic and general characteristics of the two groups.
Variables SDM CLP P Value
Sex Male 20 (58.8%) 19 (55.9%) 0.81
Female 14 (41.2%) 15 (44.1%)
Age The mean 52.2 ± 6.7 53.7 ± 7.1 0.62
<50 years old 14 (41.2%) 12 (35.3%)
≥50 years old 20 (58.8%) 22 (64.7%)
Leakage pattern Focal 22 (64.7%) 20 (58.8%) 0.62
Diffuse 12 (35.3%) 14 (41.2%)
The mean of disease duration (years) 18.1 ± 4.7 19.8 ± 4.4 0.13
The mean of IOP (mmHg) 17.94 ± 2.64 17.85 ± 3.06 0.9
The mean of refraction (Diopter) 1.22 ± 0.44 1.12 ± 0.62 0.44
Lens opacity Mild 14 (41.2%) 13 (38.2%) 0.59
Moderate 19 (55.9%) 18 (52.8%)
Severe 1 (2.9%) 3 (8.8%)
SDM: subthreshold diode laser micropulse; CLP: conventional laser photo-
coagulation; IOP: intra-ocular pressure.Also in our study, the decrease of mean CMT in Group 1
was 13 ± 3.1 microns, and 5 ± 0.4 microns after 4 months in
Group 2 (P ¼ 0.012 and P ¼ 0.049, respectively) (Table 2,
Fig. 2). Although CMT in both groups decreased significantly
after 4 months, its change was much higher in Group 1 (Table
2, Fig. 2).
The changes of central macular volume (CMV) after 4
months significantly declined in Group 1 (P ¼ 0.003), while
this decrease was not considerable Group 2 (P ¼ 0.31).
Interestingly, CMV before and during the study did not differ
much between both groups (Table 2, Fig. 3). The complica-
tions of laser therapy, including vitreous and intra-retinal
hemorrhage, choroidal neovascularization, fovea burn, andFig. 1. The mean of BCVA (LogMAR) before the treatment and 2 and 4
months after it in Group 1 treated with subthreshold diode laser micropulse
(SDM) versus Group 2 treated with conventional laser photocoagulation
(CLP).
Fig. 2. The mean of central macular thickness (CMT) (microns) before the
treatment and 2 and 4 months after it in Group 1 treated with subthreshold
diode laser micropulse (SDM) versus Group 2 treated with conventional laser
photocoagulation (CLP).
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group. Although retinal scar formation was not noticed in
Group 1, it was observed in all of the cases of Group 2.
Discussion
We studied the effect of SDM photocoagulation in com-
parison with conventional laser photocoagulation (focal or
grid) on the reduction of the CMT and the CMV. Moreover,
changes in the BCVA were compared with those of the two
laser methods.
The important cause of retinal edema is serum leakage
from abnormal decompensated endothelial cells, and the
consequence is abnormal retinal vessels in patients with dia-
betic retinopathy. There are multiple therapeutic strategies for
DME, including controlling blood sugar and hypertension and
changing lifestyle as well as ocular therapies such as intra-
vitreal corticosteroids or anti-vascular endothelia growthFig. 3. The mean of central macular volume (CMV) (mm3) before the treat-
ment and 2 and 4 months after it in Group 1 treated with subthreshold diode
laser micropulse (SDM) versus Group 2 treated with conventional laser
photocoagulation (CLP).factors (anti-VEGF), laser treatment, and ultimately surgical
pars plana vitrectomy in treating some complicated
cases.5,12e14 Laser light is absorbed by pigmented epithelium
of the retina (RPE), leading to the destruction of the RPE and
consequent diminution of retinal hypoxia due to the decrease
in the retinal oxygen demand and diffusion of oxygen through
the laser scar windows. Additionally, another hypothesis is
related to the decrease in the VEGF from destructed RPE.15,16
In the conventional method of laser photocoagulation, laser is
applied to all of the leaking microaneurysms, using green or
yellow wavelengths to treat focal form of DME, and grid
pattern of laser is used to treat all areas of leakage in diffuse
form of DME. In grid pattern laser, 500 microns are spared
from the center of macula.6 Nowadays, SDM is employed
more by ophthalmologists owing to indistinguishable retinal
scars during laser sessions or after completion of laser therapy
and much fewer complications. SDM laser therapy is an
invisible retinal phototherapy with no retinal damage by laser,
and consequently, there is no inflammatory response and loss
of functional retina. In addition, this method may increase heat
sock protein 70 expression in the RPE without inducing
cellular damage. SDM does not have any effects on neuro-
sensory retina and is absorbed by RPE.7,17e19 Cell function,
especially for those cells in the pathologic environments like
diabetes, is normalized by SDM; subsequently, cytokine pro-
duction will be affected and inflammation response will
cease.20 In this method, the laser with 810 nm wavelength is
applied. It is believed that SDM produces the same clinical
effects as the conventional laser photocoagulation in destruc-
tion of the RPEs and decreasing retinal hypoxia.17 SDM is
tolerated well by patients because of invisible infrared wave-
lengths and lesser pain sensation during laser procedure.21
Several studies have indicated a significant reduction of
CSME on OCT basis or ophthalmic examination.8,9,22e24
Furthermore, SDM has been utilized to treat proliferative
diabetic retinopathy, central serous chorioretinopathy, macular
edema due to branch retinal vein occlusion, and even
glaucoma.9,25e31 In addition, our study is the first one to
evaluate the effect of SDM, in comparison with conventional
laser photocoagulation, on the treatment of DME in Iranian
patients. According to our results, SDM is more effective than
conventional laser photocoagulation in decreasing CMT and
CMVafter 4 months in DME patients (P ¼ 0.001). BCVAwas
established in both groups with a slight improvement in eyes
treated with SDM after 4 months, but the difference between
the two groups was significant (P ¼ 0.015).
Luttrul et al showed a 24% reduction of foveal thickness
after 3 months of SDM procedure.24 One study similar to our
study was performed in Oxford Eye Hospital that compared
SDM with conventional green laser (CGL). That study did not
demonstrate any significant differences between SDM and
CGL in BCVA, retinal thickness, and contrast sensitivity.9
Ohkoshi and Yamaguchi designed a study to evaluate the
changes of visual acuity and macular edema after applying
SDM to Japanese patients. They concluded that SDM can
control the macular edema and maintain the visual acuity in
diabetic patients with moderate DME; however, they did not
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published in 2010, comparing microperimetry and fundus
autofluorescent angiography (FAF) of diabetic patients treated
with SDM versus conventional laser photocoagulation. The
retinal sensitivity increased in the group treated with SDM and
decreased in the other group. Moreover, SDM induced no
changes in FAF. It was concluded that SDM is as effective as
the conventional laser photocoagulation in treating CSME,
except that it causes fewer scar formations and increases
retinal sensitivity.8 In an observational, pilot study performed
in 2004, SDM was effective in improving or establishing vi-
sual acuity in 85% of the treated eyes, and macular edema
decreased in 96% of the treated eyes.21 In addition, anti VEGF
was employed to treat DME. Several studies, such as READ-2,
compared the effect of anti-VEGF, versus conventional laser
photocoagulation, on treating DME. In READ-2, intra-vitreal
Ranibizumab alone resulted in a 7-letter improvement after 6
months; however, laser or combination therapy (laser plus
intra-vitreal Ranibizumab) had less favorable visual acuity
improvement. After two years, although visual acuity did not
differ between groups, macular thickness significantly
improved in the Ranibizumab group.13 In addition to the
READ-2 study, a review including 1978 patients by Regnier
et al showed significant superiority of anti-VEGF treatment
compared with laser treatment. However, this review did not
show significant superiority of ranibizumab in comparison
with aflibercept.14 Thus far, few studies have focused on the
comparison of anti-VEGF and SDM. Therefore, more studies
are required in this regard.
SDM is a new technique where laser is applied to RPE with
better controlled photo thermal effect. The advantage of this
method is tissue sparing in the location of laser and its sur-
roundings. In conventional laser method, CW is used and, as a
result, the temperature rises rapidly and leads to photothermal
damage of neurosensory and inner retina. In SDM, the energy
is delivered with a train of repetitive on- and off-periods. The
time off is more than that of the “on-period” (The duration of
the “on-period” and the “off-period” is 100e300 and
1700e1900 ms, respectively). Short “on” time period limits
increase the power and temperature. During long time “off-
period”, the temperature decreases, and consequently, the
thermal injury diminishes.22,30
A small sample size, short period of the follow-up, and no
comparison with intra-vitreal anti-VEGF or corticosteroids
were the major limitations of our study. We did not quantify
the DME type based on the FA and OCT images. Also, we did
not record the quantitative data for laser shots in this study. We
recommend a study with a longer follow-up as well as a larger
sample size and evaluation scotoma by using primetry to
compare the effectiveness of these two laser treatment
methods. In addition, it is worth performing a study to
compare SDM with intra-vitreal anti-VEGF in order to mea-
sure the macular edema and visual acuity changes in patients
with DME.
In conclusion, our results revealed that SDM was more
effective than conventional laser photocoagulation in reducingCMT and CMV in patients with DME. Furthermore, the SDM
treatment leads to no retinal scars during laser procedure.
Therefore, it seems that SDM can be a good substitute for
conventional laser photocoagulation in DME treatment if
confirmed in future studies.
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